Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Optimizing melanoma models for ex vivo functional assays to predict targeted and immune therapy response
FY 2022-23
Summary
Melanoma is the deadliest form of skin cancer, due to its resistance to traditional cancer therapies. Major breakthroughs were made by treating advanced melanoma with two new kinds of therapies known as BRAF/MEK inhibitors and immune checkpoint inhibitors (ICIs). These therapies have been successful because BRAF/MEK inhibitors target the growth and survival pathways that cancer cells often rely on, and ICIs reactivate the body’s anti-tumour immune response to fight off the cancer. However, more issues arise as patients become resistant to BRAF/MEK inhibitors, meaning the drug no longer works for them, and less than 50% of patients see positive effects from ICIs. These unfortunate events are difficult to predict, so there is currently no highly effective test for clinics to use to determine the best course of treatment for individual patients. In addition, these issues can cause financial and emotional harm to patients if they receive inappropriate treatment for their cancer. Therefore, it is imperative that new tools are developed to aid doctors in making these difficult clinical decisions.
MISO Chip shows promise as a potential solution. The chip will allow scientists to directly test different kinds/combinations of treatment on tumour samples. The results obtained from the chip could then inform doctors on the best treatment strategy to follow, personalized to individual patients. However, the MISO Chip has not yet been tested and optimized specifically for melanomas. Thus, I will validate the MISO Chip by comparing drug responses of tumours using the chip with other currently used melanoma models, informing us on the chip's predictive power. Ultimately, this study will lay a foundation for future use of MISO Chip in personalized melanoma therapy.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486025
Name
Lin Tiffany
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimizing melanoma models for ex vivo functional assays to predict targeted and immune therapy response
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker Assay; Biotechnology; Braf/Mek Inhibitors; Immune Checkpoint Inhibitors (Icis); Melanoma; Microfluidic Chip; Personalized Medicine; Sirna; Targeted Therapy
Abstract
Melanoma is the deadliest form of skin cancer, due to its resistance to traditional cancer therapies. Major breakthroughs were made by treating advanced melanoma with two new kinds of therapies known as BRAF/MEK inhibitors and immune checkpoint inhibitors (ICIs). These therapies have been successful because BRAF/MEK inhibitors target the growth and survival pathways that cancer cells often rely on, and ICIs reactivate the body’s anti-tumour immune response to fight off the cancer. However, more issues arise as patients become resistant to BRAF/MEK inhibitors, meaning the drug no longer works for them, and less than 50% of patients see positive effects from ICIs. These unfortunate events are difficult to predict, so there is currently no highly effective test for clinics to use to determine the best course of treatment for individual patients. In addition, these issues can cause financial and emotional harm to patients if they receive inappropriate treatment for their cancer. Therefore, it is imperative that new tools are developed to aid doctors in making these difficult clinical decisions.
MISO Chip shows promise as a potential solution. The chip will allow scientists to directly test different kinds/combinations of treatment on tumour samples. The results obtained from the chip could then inform doctors on the best treatment strategy to follow, personalized to individual patients. However, the MISO Chip has not yet been tested and optimized specifically for melanomas. Thus, I will validate the MISO Chip by comparing drug responses of tumours using the chip with other currently used melanoma models, informing us on the chip's predictive power. Ultimately, this study will lay a foundation for future use of MISO Chip in personalized melanoma therapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lin, Tiffany
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~